Arcadia Biosciences stockholders approve 2026 equity plan and reverse split authority
At the September 10, 2026 annual meeting, stockholders approved the 2026 Omnibus Equity Incentive Plan, which succeeds the 2015 plan that expired in 2025, and approved an amendment allowing a reverse stock split of 1-for-2 to 1-for-10 if the board chooses to effect one before June 30, 2027. Stockholders also elected Gregory D. Waller as a Class II director and approved share issuance on exercise of Series A-1 Preferred Investment Options. The filing does not say whether the board will use the reverse split authority.
Key points
- Equity plan approved with 326,188 votes for, 149,113 against and 7,889 abstentions
- Reverse split authority approved with 1,120,937 votes for and 138,084 against, usable until June 30, 2027
- Gregory D. Waller elected Class II director with 377,954 votes for and 105,236 withheld, serving until 2029
- Shares present at the meeting totaled 1,259,315, about 52.3% of shares outstanding on the record date
The filing
Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 15, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.